000301264 001__ 301264
000301264 005__ 20250518020551.0
000301264 0247_ $$2doi$$a10.1016/j.esmoop.2025.105053
000301264 0247_ $$2pmid$$apmid:40345056
000301264 0247_ $$2altmetric$$aaltmetric:177034949
000301264 037__ $$aDKFZ-2025-00949
000301264 041__ $$aEnglish
000301264 082__ $$a610
000301264 1001_ $$0P:(DE-HGF)0$$aLivingstone, E.$$b0
000301264 245__ $$aEarly switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.
000301264 260__ $$a[London]$$bElsevier$$c2025
000301264 3367_ $$2DRIVER$$aarticle
000301264 3367_ $$2DataCite$$aOutput Types/Journal article
000301264 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1747133155_13899
000301264 3367_ $$2BibTeX$$aARTICLE
000301264 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000301264 3367_ $$00$$2EndNote$$aJournal Article
000301264 520__ $$aOptimal sequencing of immune checkpoint inhibitors (ICIs) and targeted therapies (TTs) in BRAFV600-positive advanced melanoma should achieve rapid tumour control and durable progression-free survival (PFS), translating into prolonged overall survival (OS).The 1 : 1 randomised phase II ImmunoCobiVem trial compared-after a 3-month run-in phase with vemurafenib (VEM, 960 mg twice daily) and cobimetinib (COB, 60 mg daily days 21-28, q4w)-continuous VEM + COB until disease progression (PD1) and second-line atezolizumab (ATEZO, 1200 mg, q3w) in arm A versus early switch to ATEZO after run-in, followed by crossover to VEM + COB at PD1, in arm B. PFS from the start of run-in until PD1 was the primary endpoint (PFS1); secondary efficacy endpoints were OS, overall PFS (PFS2) and PFS3 (time from PD1 to PD after crossover, i.e. PD2) and best overall response rates (BORRs).The final analysis (median follow-up 57.0 months, interquartile range 22.7-63.0 months) confirmed longer PFS1 for continuous TT [arm A (69 patients) versus arm B (early switch, 66 patients); hazard ratio (HR) 0.61, 95% confidence interval (CI) 0.41-0.91, P = 0.006], but early switch to ICIs resulted in better long-term OS [4- and 5-year landmark OS 42% (95% CI 29% to 55%) and 40% (95% CI 27% to 53%) for arm A, and 53% (95% CI 38% to 65%) and 45% (95% CI 31% to 58%) for arm B; descriptive HR 1.17, 95% CI 0.71-1.91]. Absolute BORRs were 81% and 89%, respectively, with 15 (22%) and 19 (29%) patients achieving a complete response at least once along each sequence. At crossover, TT retreatment (arm B) resulted in higher PFS3 than second-line ICI (arm A).Early switch to ICIs after TT run-in (arm B) led to an improved, although not statistically significant, 4- and 5-year landmark OS compared with arm A. No subgroups were identified for which a TT run-in provided clinical benefit. The number of patients developing brain metastasis and the time to brain metastasis were not improved by an early TT to ICI switch.
000301264 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000301264 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000301264 650_7 $$2Other$$acrossover design
000301264 650_7 $$2Other$$aimmunotherapy
000301264 650_7 $$2Other$$amelanoma
000301264 650_7 $$2Other$$asequential therapy
000301264 650_7 $$2Other$$atargeted therapy
000301264 7001_ $$aGogas, H. J.$$b1
000301264 7001_ $$aKandolf, L.$$b2
000301264 7001_ $$aMeier, F.$$b3
000301264 7001_ $$aEigentler, T. K.$$b4
000301264 7001_ $$aZiemer, M.$$b5
000301264 7001_ $$aTerheyden, P.$$b6
000301264 7001_ $$aGesierich, A.$$b7
000301264 7001_ $$aHerbst, R. A.$$b8
000301264 7001_ $$aKähler, K. C.$$b9
000301264 7001_ $$aZiogas, D. C.$$b10
000301264 7001_ $$aMijušković, Ž$$b11
000301264 7001_ $$aGarzarolli, M.$$b12
000301264 7001_ $$aGarbe, C.$$b13
000301264 7001_ $$0P:(DE-HGF)0$$aRoesch, A.$$b14
000301264 7001_ $$0P:(DE-HGF)0$$aUgurel, S.$$b15
000301264 7001_ $$aGutzmer, R.$$b16
000301264 7001_ $$aGaudy-Marqueste, C.$$b17
000301264 7001_ $$aKiecker, F.$$b18
000301264 7001_ $$0P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aUtikal, J.$$b19$$udkfz
000301264 7001_ $$aHartmann, M.$$b20
000301264 7001_ $$0P:(DE-HGF)0$$aMiethe, S.$$b21
000301264 7001_ $$aEckhardt, S.$$b22
000301264 7001_ $$0P:(DE-He78)8907fd1c83f2e7105a6ba98907ff9aa6$$aZimmer, Laura$$b23
000301264 7001_ $$0P:(DE-HGF)0$$aSchadendorf, D.$$b24
000301264 773__ $$0PERI:(DE-600)2844985-X$$a10.1016/j.esmoop.2025.105053$$gVol. 10, no. 5, p. 105053 -$$n5$$p105053$$tESMO open$$v10$$x2059-7029$$y2025
000301264 909CO $$ooai:inrepo02.dkfz.de:301264$$pVDB
000301264 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000301264 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000301264 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000301264 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000301264 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$aExternal Institute$$b21$$kExtern
000301264 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8907fd1c83f2e7105a6ba98907ff9aa6$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000301264 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b24$$kDKFZ
000301264 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000301264 9141_ $$y2025
000301264 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bESMO OPEN : 2022$$d2024-12-30
000301264 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-30
000301264 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-30
000301264 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:49:18Z
000301264 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:49:18Z
000301264 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T14:49:18Z
000301264 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-30
000301264 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-30
000301264 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-30
000301264 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-30
000301264 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-30
000301264 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bESMO OPEN : 2022$$d2024-12-30
000301264 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-30
000301264 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-30
000301264 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000301264 9201_ $$0I:(DE-He78)A370-20160331$$kA370$$lKKE Dermatoonkologie$$x1
000301264 980__ $$ajournal
000301264 980__ $$aVDB
000301264 980__ $$aI:(DE-He78)ED01-20160331
000301264 980__ $$aI:(DE-He78)A370-20160331
000301264 980__ $$aUNRESTRICTED